Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
Avidity Biosciences to Participate in Upcoming Investor Conference
Goldman Sachs Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $59
Avidity Biosciences: Poised for Blockbuster Success With Leading Rare Disease Therapies
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cantor Fitzgerald Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $96
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Unveiling 7 Analyst Insights On Avidity Biosciences
Avidity Biosciences(RNA.US) Officer Sells US$4.5 Million in Common Stock
Avidity Biosciences Insider Sold Shares Worth $1,010,043, According to a Recent SEC Filing
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Avidity Biosciences: Strong Buy on Promising Clinical Data and Reduced Competition
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Avidity Biosciences Price Target Maintained With a $96.00/Share by Cantor Fitzgerald
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Avidity Biosciences to Participate in Upcoming Investor Conferences
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Life Science Cares San Diego Scales Partnership With Avidity Biosciences Through Life Science Shares Program